UCLA
UCLA Previously Published Works

Title
Outpatient utilization among chronically ill patients in managed care.

Permalink
https://escholarship.org/uc/item/9f9339v4

Authors
Tisnado, D
Chen, WP
Adams, J
et al.

Publication Date
2002-04-01

Peer reviewed
There were no differences in any of the 5 subscales on the MCQ or the MAQ’s Overall, Symptom, or Activity subscales. Patients in the PH intervention group had improved MAQ Emotion (p < 0.04) and Environment scores (p < 0.03). There were also no differences in patients’ satisfaction with their physicians or pharmacists, medication compliance, emergency room visits within 6 months (p = 0.56, logistic regression), hospitalizations (p = 0.52, Fisher’s exact test), or charges ($6,261/patient). Physicians viewed guidelines as helpful reviews but reinforced “cookbook medicine” to lower health care costs.

CONCLUSION: Computer delivery of RAD care suggestions to primary care physicians and/or outpatient pharmacies did not improve patients’ subjective or objective outcomes. Effective interventions will require enhancing the message (e.g., with symptom information) or its delivery (e.g., requiring responses) or providers’ attitudes toward computers and guidelines suggesting how they should provide care.

WHAT IS THE CONCORDANCE BETWEEN PATIENT SELF-REPORT AND MEDICAL RECORD AS A DATA SOURCE FOR MEDICATION USE? D. Tantalo, W.P. Chen, H.H. Liu, J. Adams, C. Dambert, D. Carlisle, C.M. Mangione; K.L. Kahn; UCLADep of Medicine, Los Angeles, CA; RAND, Santa Monica, CA; PBGH, San Francisco, CA (Tracking ID #52180)

BACKGROUND: Medical record data may be considered the preferred data source for treatments received by patients (pts), but review is costly and often incomplete. In lieu of medical record data, pt self-report is often used, but questions arise about the completeness and validity of these data for evaluating the quality of care.

METHODS: As part of the UCLA/PBGH Physician Value Check Validation Study, we examined medication data collected using a self-administered survey and medical record abstraction for pts with diabetes, ischemic heart disease, asthma or COPD, or chronic low back pain, in 3 West Coast states. We surveyed 1656 patients from participating medical organizations (response rate 63%). The mailed, self-administered survey queried pts about utilization of health services and process of care over the same time window, as well as about prescription use. MRs for pts with survey data were reviewed and abstracted by trained nurses to collect data from the same time window. We evaluated concordance between the 2 data sources for the following prescription med categories: lipid-lowering meds including statins, antidepressants, ACE inhibitors for 1270 pts; sulfonylureas for 408 pts with diabetes; beta blockers for 338 pts with heart disease; and inhaled corticosteroids for 338 pts with asthma or COPD, using the McNemar’s Chi square test, kappa statistic, and the Sensitivity and Specificity of the self-report (using the MR as the gold standard). We compared levels of concordance by age category (vs 50 – 64 vs 65+ yrs), race/ethnicity (non-Hispanic white vs other), education (≤12 years vs ≥12 years) and annual income ($<30K vs $≥30K).

RESULTS: Using data from pts with both survey and MR review, we analyzed a subset of data for pts with at least one visit to a clinician during the two-year study window (n = 1270). The % of pts who used a medication to both data sources ranged from 11% for antidepressants among all pts to 44% for sulfonylureas among diabetic pts. Kappa statistics ranged from 0.57 for antidepressants to 0.76 for beta-blockers indicating fair to good agreement between data sources beyond what would be expected by chance alone. Sensitivity ranged from 51% for anti-depressants to 78% for beta-blocker use. Specificity ranged from 88% for sulfonylureas use to 98% for anti-depressant use. Concordance between data sources varied by patient age, race/ethnicity, education and income, with lower levels of concordance associated with older age group, non-white race/ethnicity, and lower education and income levels.

CONCLUSION: Reviewing a function of data source with concordance between data sources varying by patient characteristics. Quality of care scores may be affected. * p < .05 for Test of Equal Kappa coefficients.

OUTPATIENT UTILIZATION AMONG CHRONICALLY ILL PATIENTS IN MANAGED CARE. D. Tantalo, W.P. Chen, J. Adams, H.H. Liu, C. Dambert, D. Carlisle, C.M. Mangione; K.L. Kahn; UCLADepartment of Medicine, Los Angeles, CA; RAND, Santa Monica, CA; PBGH, San Francisco, CA (Tracking ID #52310)

BACKGROUND: Although inpatient utilization in managed care organizations has been studied extensively, less is known about outpatient utilization. We utilized the number of visits and providers seen by a cohort of chronically ill patients to assess outpatient utilization using claims/encounter data (C/E) and from medical records (MR).

METHODS: As part of the UCLA/PBGH Validation Study, we obtained consent for review of C/E data from 48 (83%) of 58 medical organizations for 63% of 2287 chronically ill patients in 3 West Coast states. 38 medical organizations provided C/E data for these patients for a 24-month window. Medical records for patients with C/E data were reviewed and abstracted by trained nurses. C/E and MR data from 1556 patients from 34 (71%) of 48 consenting medical organizations. We excluded 11 patients with no claims or encounters during the 24-month study period, for a total of 1448 patients.

RESULTS: Using data from patients with claims/encounters, and medical record data for the same 24 month window, we analyzed a subset of data for patients with at least one visit to a clinician (i.e., physician or nurse practitioner) (n = 1148). Based on C/E and medical record data, the mean number of visits to a clinician during the study window was 23, including 11 visits to a primary care provider (PCP). Visit frequency varied by disease, from a mean of 19 for patients with low back pain to 26 for patients with diabetes. Patients saw a mean of 6 unique providers. We also examined the unique contribution of medical record data as compared with C/E data alone. Over 8% of visits and 3% of clinicians would not have been measured using C/E data alone. Medical record data provided additional information that was not captured by the C/E data for 300 patients (26%). With the addition of medical record data, 4% more patients were noted to have had ≥1 PCP visit, 4% more heart patients were noted to have had ≥1 cardiology visit, and 3% more diabetes patients were noted to have had ≥1 eye exam.

CONCLUSION: Outpatient utilization among chronically ill patients in managed care has been understudied. Concordance between C/E and MR data was substantial, with more patients identified in MR for many chronic conditions. A greater number of patients had ≥6 visits in the medical record review than noted in C/E data. Although less expensive and time consuming to obtain and use relative to medical record data, C/E data alone do not capture the complete experience of direct patient care.

PERSISTENCE OF THE USE OF CARDIOVASCULAR MEDICATIONS: DOES PAY TO ABILITY MATTER? J. Weiss1; J. Schwartz2; 1University of Pennsylvania, Philadelphia, PA; 2Thomas Jefferson University, Philadelphia, PA (Tracking ID #51792)

BACKGROUND: Little is known about patients who discontinue antihypertensive or lipid-lowering therapy. We sought to identify factors associated with non-persistence, and how these factors differ for antihypertensive versus lipid-lowering medications.

METHODS: We conducted a cross-sectional study from the 1998 National Health Interview Survey (NHIS), a population-based survey of households in the United States. Subjects were asked whether they had ever received a prescription for blood pressure or cholesterol lowering medication, whether they were currently taking the medication, and whether during the past 12 months there was any time when they could not afford their prescription medications. We used bivariate and multivariate analyses to identify risk factors for non-persistence of medication therapy.

RESULTS: Of 5,297 adults who received a prescription for blood pressure treatment, overall 13% stopped medication use. Discontinuation differed across age groups (+65 vs ≤65 yrs: 17.9% vs 7.7%; p < 0.001) and health insurance coverage (coverage vs no coverage: 36.3% vs 11.5%; p < 0.0001). Of the 1,731 adults who used cholesterol-lowering medications, overall 23% stopped medication use. In addition, there were associations with differences in discontinuation of cholesterol treatment ($20,000 vs ≤$2,000: 27% vs 21%; p < 0.001). Overall, 7% reported they could not afford their medication in the past 12 months. Among subjects who discontinued use without the consent of their physician, the beneficiaries were more likely to use up their annual drug benefits and to determine the top medications driving the cost pharmacy for these beneficiaries. These medications were evaluated for availability of generic substitutes and potential replacement with lower cost medications in both same and different therapeutic classes.

CONCLUSION: The proportion of patients predicted to exceed their annual outpatient benefit before the end of the year ranged from 1 in 4 for a $750 benefit to 1 in 12 for those with a $2000 benefit. The top twenty medications driving the pharmacy cost for these beneficiaries were similar across all benefit levels. Fifteen of these medications were for the management of chronic conditions such as hypertension, hyperlipidemia, diabetes, osteoporosis, and emphysema/asthma. Two other medications were for the treatment of pain and another two drugs were for management of reflux/pacitic ulcer disease. A thirty-pill supply for these medications ranged from $28 to $540, based on commonly available online pharmacy prices. Only two drugs out of twenty were available in generic form in 2001. Potential cost-savings were possible for many of the medications but only by changing to less expensive medications with different side effect profiles (for example from Cox-2 Inhibitors to Non-Steroidal Anti-Inflammatory medications).

CONCLUSION: Medications driving drug costs for these Medicare beneficiaries were mostly for chronic diseases and did not have generic substitutes. Physicians can play an important role in helping Medicare + Choice members make the most of their limited drug benefits by discontinuing unnecessary medications and by helping patients weigh the risk and benefits of using lower cost medications that are also indicated for the management of many of their chronic conditions.

EFFECT OF LINKAGE OF MEDICAL CARE TO DRUG TREATMENT ON HOSPITALIZATION OF DRUG USERS WITH HIGH VERSUS LOW MEDICAL EXPENDITURE. B.J. Turner1, C. Lane2, W.W. Hauck3; 1University of Pennsylvania, Philadelphia, PA; 2Aetna Inc., Philadelphia, PA; 3Thomas Jefferson University, Philadelphia, PA (Tracking ID #52154)

BACKGROUND: Drug abuse is associated with substantial medical morbidity and demand for inpatient care. Improved delivery of medical care for drug users in drug treatment may improve health status and consequently reduce hospitalization. We examined the association of providing medical care onsite or in the same building as a drug treatment clinic on hospitalization of drug users with addictive co-morbidities in managed care organizations.

METHODS: We studied drug users enrolled in New York State Medicaid for ≥10 mos of both 1996 and 1997. We conducted surveys of directors of 125 methadone and/or medically-supervised drug free programs in 1998 regarding about linkage of medical care services in 1996–97. Responses reporting general and HIV medical care onsite or in the same building...